Three series of curcumin derivatives including phosphorylated, etherified, and esterified products of curcumin were synthesized, and their anti-tumor activities were assessed against human breast cancer MCF-7, hepatocellular carcinoma Hep-G2, and human cervical carcinoma HeLa cells. Compared with curcumin, compounds 3, 8, and 9 exhibited stronger antitumor cell line growth activities against HeLa cells. Compound 12 also showed higher antitumor cell line growth activities on MCF-7 cells than curcumin. Among them, 4-((1E,6E)-7-(4-Hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl)-2-methoxyphenyl dihydrogen phosphate(3) showed the strongest activity with an half maximal inhibitory concentration (IC50) of 6.78 µM against HeLa cells compared with curcumin with an IC50 of 17.67 µM. Stabilities of representatives of the three series were tested in rabbit plasma in vitro, and compounds 3 and 4 slowly released curcumin in plasma. The effect of compound 3 on HeLa cell apoptosis was determined by examining morphological changes by DAPI (4′,6-diamidino-2-phenylindole) staining as well as Annexin V-FITC/ Propidium Iodide (PI) double staining and flow cytometry. The results showed that 3 induced cellular apoptosis in a dose-dependent manner. Together our findings show that 3 merits further investigation as a new potential antitumor drug candidate.
合成了三类
姜黄素衍
生物,包括
磷酸化、醚化和
酯化的
姜黄素产品,并评估了它们对人乳腺癌
MCF-7、肝细胞癌Hep-G2和人宫颈癌HeLa细胞的抗肿瘤活性。与
姜黄素相比,化合物3、8和9在对HeLa细胞的抗肿瘤细胞生长活性方面表现出更强的活性。化合物12在
MCF-7细胞上的抗肿瘤细胞生长活性也高于
姜黄素。其中,化合物4-((1E,6E)-7-(
4-羟基-3-
甲氧基苯基)-3,5-二
氧杂庚-1,6-二
烯基)-2-
甲氧基苯基二
氢磷酸(3)表现出最强的活性,对HeLa细胞的半最大抑制浓度(IC50)为6.78 µM,而
姜黄素的IC50为17.67 µM。在体外测试了这三类代表化合物在兔血浆中的稳定性,化合物3和4在血浆中缓慢释放
姜黄素。通过
DAPI(4′,6-二
氨基-
2-苯基吲哚)染色以及Annexin V-FITC/
碘化丙锭(
PI)双重染色和流式细胞术,确定了化合物3对HeLa细胞凋亡的影响。结果显示,化合物3以剂量依赖的方式诱导细胞凋亡。综上所述,我们的研究结果表明,化合物3值得进一步研究作为新的潜在
抗肿瘤药物候选者。